Epilepsy Talk
$56,000 a year for an unproven drug!
Leave a Comment
Getting the FDA to retract a decision, is like getting the toothpaste back in the tube, after it’s been squeezed out…
Whether it’s “yes” or “no,” there is no “maybe so”.
A good example is the new all star Alzheimer’s drug aducanumab.
Whether it’s “yes” or “no,” there is no “maybe so”.
Tags: $56000 a year, aducanumab, Alzheimer’s, efficiency, FDA, not proven, patients, risk, side-effects
$112 billion new Alzheimer’s drug in question
4 Comments
Getting the FDA to retract a decision is like getting the toothpaste back in the tub, after it’s been squeezed out…
Whether it’s “yes” or “no,” there is no “maybe so”.
A good example is the new all star Alzheimer’s drug aducanumab.
Tags: $112 billion costs, &56000 a year, alzheimer's, FDA, Medicare, not proven, side effects
The first new Alzheimer’s drug in 18 years may not work.
Leave a Comment
Getting the FDA to retract a decision is like getting the toothpaste back in the tub, after it’s been squeezed out…
Whether it’s “yes” or “no,” there is no “maybe so”.
A good example is the new all-star Alzheimer’s drug aducanumab.
Tags: $5600 a year, aducanumab, Alzheimer's drug, amyloid plaque, billions of dollars, caregiver, FDA, Medicare, not proven
About the author
Epilepsy Talk 